IN
INIS.US International Isotopes Inc
- Market cap
- USD 26.5M
- P/E
- -
- P/B
- 13.39x
- ROE
- -235.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is INIS.US undervalued?
Graham numberThe Graham number of International Isotopes Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
International Isotopes Inc fundamental analysis
No fundamental analysis for International Isotopes Inc yet.
International Isotopes Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About International Isotopes Inc
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug…
Full company profileInternational Isotopes Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
International Isotopes Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.55M | 7.42M | 10.4M | 8.96M | 9.36M | 9.66M | 11.2M | 12.3M | 13.9M | 13.1M | 10.1M |
| Gross Profit | 2.84M | 3.24M | 4.69M | 4.67M | 5.46M | 5.74M | 6.29M | 7.38M | 8.65M | 7.70M | 5.02M |
| Operating Income | -1.50M | -2.07M | -290K | -558K | -416K | -681K | -1.20M | -776K | 6.90K | -956K | -4.29M |
| EBITDA | - | -2.97M | 73.9K | -392K | 3.56M | 608K | 1.29M | -187K | 738K | -166K | -3.67M |
| Net Income | -1.88M | -3.76M | -845K | -1.52M | 2.20M | -902K | 303K | -869K | 8.57K | -908K | -4.46M |
| EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 11.4M | 12.0M | 13.0M | 15.3M | 17.1M | 16.3M | 16.2M | 16.9M | 17.2M | 17.8M | 16.6M |
| Total Liabilities | 9.62M | 11.7M | 12.8M | 15.4M | 14.2M | 13.6M | 11.9M | 12.9M | 12.8M | 14.1M | 14.8M |
| Shareholders' Equity | 1.76M | 347K | 154K | -112K | 2.89M | 2.73M | 4.34M | 4.04M | 4.35M | 3.69M | 1.89M |
| Cash & Short-term Investments | 315K | 409K | 828K | 575K | 1.11M | 475K | 2.38M | 2.69M | 1.95M | 1.70M | 1.20M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -324K | -466K | 97.2K | -53.6K | 1.15M | -162K | -1.50M | 583K | 639K | 620K | -1.37M |
| Capital Expenditure | 93.6K | 110K | 86.3K | 208K | 7.74K | 205K | 120K | 149K | 721K | 534K | 410K |
| Free Cash Flow | - | -963K | 10.8K | -262K | 1.14M | -367K | -1.62M | 434K | -82.4K | 86.0K | -1.78M |
| Ratios | |||||||||||
| ROE | -107.0% | -1,083.0% | -547.9% | - | 76.3% | -33.0% | 7.0% | -21.5% | 0.2% | -24.6% | -235.7% |
| ROA | -16.5% | -31.3% | -6.5% | -10.0% | 12.9% | -5.5% | 1.9% | -5.1% | 0.0% | -5.1% | -26.8% |
| Net Profit Margin | -28.7% | -50.6% | -8.1% | -17.0% | 23.5% | -9.3% | 2.7% | -7.1% | 0.1% | -6.9% | -44.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
International Isotopes Inc dividends
International Isotopes Inc has not paid dividends in the last 9 fiscal years.
Who owns International Isotopes Inc
- Insiders 73.47%
- Institutions 0.00%
- Public & others 26.53%
- Shares outstanding 529M
- Free float 347M
International Isotopes Inc company profile
- Company name
- International Isotopes Inc
- Ticker
- INIS.US
- Exchange
- USA Stocks
- Listed since
- Aug 14, 1997
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 44
- Fiscal year end
- December
- Address
- 4137 Commerce Circle, Idaho Falls, ID, United States, 83401
- Phone
- 208 524 5300
- Website
- radnostix.com
About International Isotopes Inc
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
International Isotopes Inc management
2- Mr. Shahe BagerdjianPresident, CEO & Director · born 1984
- Mr. W. Matthew Cox B.S., CPACFO & Secretary · born 1984